Endeavor capitalist William Doyle should raise $35 million for a portfolio business with an appealing, unique cancer treatment, simply as international capital markets are imploding in the fall of 2008. Doyle thinks NovoCure has the possible to end up being an essential business with a significant brand-new cancer treatment platform, however need to finish critical (Phase III) medical trials and get FDA approval.
NovoCure Ltd. Case Study Solution
Doyle's endeavor capital company, WFD Ventures, has actually invested $25 million in 3 rounds to money pilot medical trials for glioblastoma and other non-small cell lung cancer, and the very first critical medical trial for glioblastoma. In the fall of 2008 Doyle was working out the last terms of a financial investment by 2 popular hedge funds when the liquidity crisis triggered the hedge funds to withdraw from the deal.
PUBLICATION DATE: November 24, 2009 PRODUCT #: 810045-HCB-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
Deloitte: on Livent Inc.
Long-Term FX Strategies in 2008
Global Property and Casualty Insurance Industry
Catawba Industrial Co.
The Politics and Economics of Accounting for Goodwill at Cisco Systems (B)
Global Fabricators, Inc.
Callmate Telips (B): Orix Investment Bank Pakistan Limited – Callmate Risk Uncovered
Filling a Hole: The Reinvestment Fund and Progress Plaza
Bank Valuation Issues
Dividend Policy at Linear Technology, Spanish Version
